Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yup...nice buy for the CEO...🥳
Lol offering upsized right after the news..
in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m.
yup and time to go up even more let's pass 7 and up trmw
UPstink today
Any other bio cheapies besides hook
Was that you 3.12 big
FROM 2.92 MY CALL.NOW 3.38:))))
AS OF NOW PER SCHWAB IT IS VERY HARD TO FIND SHARES TO SHORT.WELL THAT IS GOING TO BE A B$TCH FOR SHORTS.
ORCA IS LOOKING TO GET BACK IN AGAIN.THE PPS IS COMING DOWN TO MY ENTERING PRICES:)))
“Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”
Grabbed $3.50’s..should find out who they partnered with..soon enough
Up 12% 2nd million..let’s see 3rd
Yall musta seen 911 trade..bout40min before $3.80’s breakout l..yesterday
“Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference”
$5 would be nice
Inherent risk in industry..temporary
THIS POS IS LOSING AN ENORMOUS AMOUNT OF MONEY.IT SHOULD BE TRADING IN THE .30 AREA.MAX.
Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022.
•
Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.
•
Research and development expenses for the quarter ended September 30, 2023 were $4.2 million compared to $6.0 million for the same period in 2022. The $1.8 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors.
•
General and administrative expenses for the quarter ended September 30, 2023 were $2.4 million compared to $2.8 million for the same period in 2022. The decrease was primarily due to a decrease in consulting and professional expenses and personnel costs.
Year-to-Date
•
Net cash used in operations for the nine months ended September 30, 2023 was $21.2 million.
•
Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.
Research and development expenses for the nine months ended September 30, 2023 were $13.3 million compared to $16.7 million for the same period in 2022. The $3.4 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors, partially offset by an increase in facilities expenses.
•
General and administrative expenses for the nine months ended September 30, 2023 were $8.3 million compared to $9.0 million for the same period in 2022. The $0.7 million decrease was primarily due to a decrease in consulting and professional expenses.
Nice premarket movement on earnings report..no chart signal lmao.
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
573
|
Created
|
04/04/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |